SELECT-HD ASO study sponsored by WAVE recrutis at GHI
The SELECT-HD study offered by WAVE Therapeutics with an allele-specific ASO for SNP3 is still looking for participants in Germany. We are looking for patients with symptoms in the early stages of the disease. In the case of clinical suitability for the study, a blood sample is first examined from each test person to determine whether the genetic characteristic of SNP3 is present in the region of the Huntington gene. If that's the case, participation in the study is generally possible. After the randomized phase of the study, all patients have the possibility to take part in an open-label study in which the ASO is made accessible to all study participants.
Interested parties can contact our outpatient clinic. The study is supported by the European Huntington's Network.